ES2570570T3 - Método para determinar la constante de unión de compuestos de alta afinidad - Google Patents

Método para determinar la constante de unión de compuestos de alta afinidad

Info

Publication number
ES2570570T3
ES2570570T3 ES11706799T ES11706799T ES2570570T3 ES 2570570 T3 ES2570570 T3 ES 2570570T3 ES 11706799 T ES11706799 T ES 11706799T ES 11706799 T ES11706799 T ES 11706799T ES 2570570 T3 ES2570570 T3 ES 2570570T3
Authority
ES
Spain
Prior art keywords
compound
interest
affinity
protein
sink
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11706799T
Other languages
English (en)
Inventor
Frauke Assmus
Holger Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2570570T3 publication Critical patent/ES2570570T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/24—Dialysis ; Membrane extraction
    • B01D61/243—Dialysis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/24—Dialysis ; Membrane extraction
    • B01D61/28—Apparatus therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5025—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures for parallel transport of multiple samples
    • B01L3/50255—Multi-well filtration
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5302—Apparatus specially adapted for immunological test procedures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0609—Holders integrated in container to position an object
    • B01L2300/0618—Holders integrated in container to position an object for removable separation walls
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0809—Geometry, shape and general structure rectangular shaped
    • B01L2300/0829—Multi-well plates; Microtitration plates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0848—Specific forms of parts of containers
    • B01L2300/0858—Side walls

Abstract

Método para determinar la constante de unión de un compuesto de alta afinidad de interés a proteínas, comprendiendo las etapas siguientes: a) adición de compuesto de alta afinidad a un sistema de dos cámaras, en el que las dos cámaras están separadas por una membrana semipermeable, que es permeable al compuesto de interés, y determinación de la cantidad del compuesto de alta afinidad de interés en una de las cámaras tras alcanzarse el equilibrio de distribución, b) adición de un agente acomplejante como compuesto sumidero a una de las cámaras, en el que el compuesto sumidero es una sustancia que reduce significativamente la afinidad del compuesto de interés para una proteína no específica; dicha proteína no específica se une a un amplio abanico de compuestos y el compuesto sumidero no permea la membrana, y determinación del coeficiente de distribución del compuesto de interés respecto al compuesto sumidero tras alcanzarse el equilibrio de distribución, c) adición de una proteína del plasma como proteína no específica a la otra cámara, en la que la proteína del plasma no puede permear la membrana, y determinación del coeficiente de distribución del compuesto de interés respecto a la proteína del plasma en presencia de un compuesto sumidero tras alcanzarse el equilibrio de distribución, y d) determinación de la constante de unión del compuesto de alta afinidad de interés con el coeficiente de distribución de las etapas b) y c), y en la que el compuesto de alta afinidad de interés se refiere a un compuesto que bajo condiciones fisiológicas y en presencia de un exceso de proteína del plasma, por lo menos el 95% de la cantidad total del mismo se encuentra unida a dicha proteína del plasma.
ES11706799T 2010-02-25 2011-02-22 Método para determinar la constante de unión de compuestos de alta afinidad Active ES2570570T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10154696 2010-02-25
PCT/EP2011/052550 WO2011104210A1 (en) 2010-02-25 2011-02-22 Method for determining the binding constant of high affinity compounds

Publications (1)

Publication Number Publication Date
ES2570570T3 true ES2570570T3 (es) 2016-05-19

Family

ID=43836798

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11706799T Active ES2570570T3 (es) 2010-02-25 2011-02-22 Método para determinar la constante de unión de compuestos de alta afinidad

Country Status (12)

Country Link
US (2) US8778617B2 (es)
EP (1) EP2539051B1 (es)
JP (1) JP5637608B2 (es)
KR (1) KR101521688B1 (es)
CN (1) CN102770195B (es)
BR (1) BR112012016061A2 (es)
CA (1) CA2788054C (es)
ES (1) ES2570570T3 (es)
HK (1) HK1177710A1 (es)
MX (1) MX343375B (es)
RU (1) RU2573505C2 (es)
WO (1) WO2011104210A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012016061A2 (pt) * 2010-02-25 2020-09-08 F. Hoffman-La Roche Ag "método para determinar a constante de ligação de um composto de interesse às proteínas"

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1088589A3 (en) * 1999-09-30 2003-06-18 Pfizer Products Inc. Micro-equilibrium dialysis vertically loaded apparatus
DE19952568C2 (de) * 1999-11-02 2003-05-22 Noxxon Pharma Ag Fluoreszenzmarkierte Nukleinsäure-Liganden
GB0003234D0 (en) * 2000-02-11 2000-04-05 Pfizer Ltd Method of treatment
DE10012120A1 (de) * 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
CN1170138C (zh) * 2001-02-23 2004-10-06 国家药品监督管理局天津药物研究院 平衡透析装置
US20030213740A1 (en) 2001-06-05 2003-11-20 Andrew Creasey Multi-well equilibrium dialysis systems
JP2004303186A (ja) * 2003-03-20 2004-10-28 Sumitomo Pharmaceut Co Ltd 蛋白結合率の予測に関する装置およびその方法
CN1331608C (zh) * 2005-08-02 2007-08-15 天津大学 中空膜管式微萃取分析器及其应用方法
US20070215538A1 (en) 2006-03-20 2007-09-20 Harvard Apparatus, Inc. Systems and methods for equilibrium dialysis
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
CN1939348A (zh) * 2006-09-22 2007-04-04 中国药科大学 一种中药有效成分的筛选方法
BR112012016061A2 (pt) * 2010-02-25 2020-09-08 F. Hoffman-La Roche Ag "método para determinar a constante de ligação de um composto de interesse às proteínas"

Also Published As

Publication number Publication date
BR112012016061A2 (pt) 2020-09-08
CN102770195A (zh) 2012-11-07
JP5637608B2 (ja) 2014-12-10
CN102770195B (zh) 2015-03-04
EP2539051A1 (en) 2013-01-02
JP2013519078A (ja) 2013-05-23
RU2573505C2 (ru) 2016-01-20
US8778617B2 (en) 2014-07-15
EP2539051B1 (en) 2016-03-30
MX2012009185A (es) 2012-08-23
CA2788054C (en) 2018-08-14
US20140273279A1 (en) 2014-09-18
KR101521688B1 (ko) 2015-05-19
RU2012139183A (ru) 2014-03-27
KR20120123107A (ko) 2012-11-07
MX343375B (es) 2016-11-03
CA2788054A1 (en) 2011-09-01
HK1177710A1 (en) 2013-08-30
WO2011104210A1 (en) 2011-09-01
US20120309109A1 (en) 2012-12-06

Similar Documents

Publication Publication Date Title
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
BR112012009289A8 (pt) Método para purificar um anticorpo anti-il-13 a partir de uma mistura de amostra que compreende um anticorpo anti-il-13 e pelo menos uma proteína de célula hospedeira (hcp)
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
EA201390147A1 (ru) Система циркуляции
SG10201907215QA (en) Antibodies Comprising An Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, Il-8-Binding Antibodies, And Uses Therof
BR112018010933A2 (pt) anticorpos multiespecíficos
BR112018003127A2 (pt) purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes
EA201592192A1 (ru) Способ очистки моноклональных антител
EA201490825A8 (ru) Tdp-43-специфически связывающие молекулы
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
BRPI0612612A2 (pt) compàsitos de celulose reconstituÍdos por lÍquido iânico como matrizes de suporte sàlido
EA201190144A1 (ru) Изотиазолилоксифениламидины и их применение в качестве фунгицидов
WO2015056237A3 (en) Purification of proteins
UA106875C2 (uk) Тіадіазолілоксифеніламідини та їх застосування як фунгіцидів
BR112017019774A2 (pt) uso de uma membrana capilar porosa para determinar a quantidade de produtos de am-plificação por círculo rolante
BR112017025459A2 (pt) composição, método para tratamento de doença falciforme, kit, método para detecção de polissulfato pentosano de sódio (pps)
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
BR112018001748A2 (pt) ?método de preparação de amostras e uso do método?
BR112013007871A2 (pt) quantificação e caracterização de alérgenos
CA2863661C (en) Diagnostic peptides for lyme disease
BR112016023680A2 (pt) ?processo de purificação de gonadotropina?
BR112013000840A2 (pt) método para aumentar o efeito de forma ativada potencializada de anticorpo para molécula endógena biológica, composição farmacêutica e uso de combinação de molécula biológica endógena com forma ativada potencializada de anticorpo para a sintase no endotelial.
EA201492059A1 (ru) Твердые формы фидаксомицина и способы их получения